Theravance Biopharma Insider Filing: RSU Tax Withholding Reduces Shares by 9,096

Rhea-AI Filing Summary

Rhonda Farnum, Senior Vice President, Commercial & Medical Affairs at Theravance Biopharma (TBPH), reported a Form 4 disclosing a routine share withholding on 08/20/2025 to satisfy tax obligations from the vesting of previously granted restricted stock units. The filing shows 9,096 ordinary shares were withheld at an effective price of $13.39 per share; no open-market sale occurred. After the withholding, Farnum beneficially owned 317,822 shares of TBPH. The Form 4 is filed individually and signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Withholding occurred via issuer, not an open-market sale, indicating the company handled tax obligations administratively
• Substantial remaining ownership: the reporting person retains 317,822 shares after withholding

Negative

• Reduction in beneficial ownership of 9,096 shares due to tax withholding on vested RSUs

Insights

Securities Analyst

TL;DR: A routine tax-withholding on vested RSUs reduced insider holdings by 9,096 shares; no open-market selling occurred.

This Form 4 documents a standard administrative transaction where shares were withheld by the issuer to cover tax obligations arising from RSU vesting. The transaction code used is "F," indicating shares withheld for tax withholding. The price listed ($13.39) reflects the per-share value applied to the withholding; the reporting person still retains substantial beneficial ownership at 317,822 shares. Such transactions are typically neutral for investors absent concurrent open-market sales or large ownership shifts.

Corporate Governance Expert

TL;DR: Administrative withholding tied to compensation vesting; no governance red flags or material change in control reported.

The filing specifies that the withholding was executed with the issuer and did not involve an open-market transaction, which is consistent with company-managed tax withholding on equity compensation. The filing was signed by an attorney-in-fact and lists Farnum's role as SVP, confirming officer status. There are no indications of unusual timing, related-party transactions, or departures that would raise governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/20/2025		F		9,096(1)	D	$13.39	317,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A. Grimaud, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Rhonda Farnum report on Form 4 for TBPH?

The filing reports that 9,096 ordinary shares were withheld on 08/20/2025 to satisfy tax obligations from vested restricted stock units.

Was the share withholding an open-market sale reported in the Form 4?

No. The explanation states the share withholding was with the issuer and did not involve an open market transaction.

How many TBPH shares does the reporting person own after the transaction?

After the withholding, the reporting person beneficially owned 317,822 shares of TBPH.

What price is shown on the Form 4 for the withheld shares?

The Form 4 lists a price of $13.39 per share for the withheld 9,096 shares.

What is Rhonda Farnum's role at Theravance Biopharma as indicated on the filing?

The filing identifies Rhonda Farnum as SVP, Commercial & Medical Affairs and an officer of the issuer.